Evidence From Family Studies for Autoimmunity in Arrhythmogenic Right Ventricular Cardiomyopathy: Associations of Circulating Anti-Heart and Anti-Intercalated Disk Autoantibodies With Disease Severity and Family History.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
14 04 2020
Historique:
pubmed: 3 3 2020
medline: 2 2 2021
entrez: 3 3 2020
Statut: ppublish

Résumé

Serum anti-heart autoantibodies (AHAs) and anti-intercalated disk autoantibodies (AIDAs) are autoimmune markers in myocarditis. Myocarditis has been reported in arrhythmogenic right ventricular cardiomyopathy (ARVC). To provide evidence for autoimmunity, we searched for AHAs and AIDAs in ARVC. We studied: 42 ARVC probands, 23 male, aged 42, interquartile range 33-49, 20 from familial and 22 nonfamilial pedigrees; 37 clinically affected relatives (ARs), 24 male aged 35, interquartile range 18-46; and 96 healthy relatives, 49 male, aged 27, interquartile range 17-45. Serum AHAs and AIDAs were tested by indirect immunofluorescence on human myocardium and skeletal muscle in 171 of the 175 ARVC individuals and in controls with noninflammatory cardiac disease (n=160), ischemic heart failure (n=141), and healthy blood donors (n=270). Screening of 5 desmosomal genes was performed in probands; when a sequence variant was identified, cascade family screening followed, blind to immunologic results. AHA frequency was higher (36.8%) in probands, ARs (37.8%), and healthy relatives (25%) than in noninflammatory cardiac disease (1%), ischemic heart failure (1%), or healthy blood donors (2.5%; The presence of AHAs and AIDAs provides evidence of autoimmunity in the majority of familial and in almost half of sporadic ARVC. In probands and in ARs, these antibodies were associated with features of disease severity. Longitudinal studies are needed to clarify whether they may predict ARVC development in healthy relatives or if they be a result of manifest ARVC.

Sections du résumé

BACKGROUND
Serum anti-heart autoantibodies (AHAs) and anti-intercalated disk autoantibodies (AIDAs) are autoimmune markers in myocarditis. Myocarditis has been reported in arrhythmogenic right ventricular cardiomyopathy (ARVC). To provide evidence for autoimmunity, we searched for AHAs and AIDAs in ARVC.
METHODS
We studied: 42 ARVC probands, 23 male, aged 42, interquartile range 33-49, 20 from familial and 22 nonfamilial pedigrees; 37 clinically affected relatives (ARs), 24 male aged 35, interquartile range 18-46; and 96 healthy relatives, 49 male, aged 27, interquartile range 17-45. Serum AHAs and AIDAs were tested by indirect immunofluorescence on human myocardium and skeletal muscle in 171 of the 175 ARVC individuals and in controls with noninflammatory cardiac disease (n=160), ischemic heart failure (n=141), and healthy blood donors (n=270). Screening of 5 desmosomal genes was performed in probands; when a sequence variant was identified, cascade family screening followed, blind to immunologic results.
RESULTS
AHA frequency was higher (36.8%) in probands, ARs (37.8%), and healthy relatives (25%) than in noninflammatory cardiac disease (1%), ischemic heart failure (1%), or healthy blood donors (2.5%;
CONCLUSIONS
The presence of AHAs and AIDAs provides evidence of autoimmunity in the majority of familial and in almost half of sporadic ARVC. In probands and in ARs, these antibodies were associated with features of disease severity. Longitudinal studies are needed to clarify whether they may predict ARVC development in healthy relatives or if they be a result of manifest ARVC.

Identifiants

pubmed: 32114801
doi: 10.1161/CIRCULATIONAHA.119.043931
doi:

Substances chimiques

Autoantibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1238-1248

Auteurs

Alida L P Caforio (ALP)

Division of Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health (A.L.P.C, A.I.-B., C.-Y.C., S.I.), University of Padova, Italy.

Federica Re (F)

I Cardiology Division, San Camillo Hospital, Rome, Italy (F.R., A.A., P.B., E.Z.).

Andrea Avella (A)

I Cardiology Division, San Camillo Hospital, Rome, Italy (F.R., A.A., P.B., E.Z.).

Renzo Marcolongo (R)

Department of Medicine, Hematology and Clinical Immunology (R.M.), University of Padova, Italy.

Pasquale Baratta (P)

I Cardiology Division, San Camillo Hospital, Rome, Italy (F.R., A.A., P.B., E.Z.).

Mara Seguso (M)

Department of Laboratory Medicine (M.S., N.G., M.P.), University of Padova, Italy.

Nicoletta Gallo (N)

Department of Laboratory Medicine (M.S., N.G., M.P.), University of Padova, Italy.

Mario Plebani (M)

Department of Laboratory Medicine (M.S., N.G., M.P.), University of Padova, Italy.

Alvaro Izquierdo-Bajo (A)

Division of Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health (A.L.P.C, A.I.-B., C.-Y.C., S.I.), University of Padova, Italy.

Chun-Yan Cheng (CY)

Division of Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health (A.L.P.C, A.I.-B., C.-Y.C., S.I.), University of Padova, Italy.

Petros Syrris (P)

University College London and Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, UK (P.S., P.M.E.).

Perry M Elliott (PM)

University College London and Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, UK (P.S., P.M.E.).

Giulia d'Amati (G)

Department of Radiological, Oncological, and Anatomo-pathological Sciences, Sapienza University of Rome, Italy (G.d'A.).

Gaetano Thiene (G)

Cardiovascular Pathology Unit (G.T., C.B.), University of Padova, Italy.

Cristina Basso (C)

Cardiovascular Pathology Unit (G.T., C.B.), University of Padova, Italy.

Dario Gregori (D)

Statistics, Department of Cardiac, Thoracic, Vascular Sciences and Public Health (D.G.), University of Padova, Italy.

Sabino Iliceto (S)

Division of Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health (A.L.P.C, A.I.-B., C.-Y.C., S.I.), University of Padova, Italy.

Elisabetta Zachara (E)

I Cardiology Division, San Camillo Hospital, Rome, Italy (F.R., A.A., P.B., E.Z.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH